Global Vision
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
2024 Radar: UK Medtechs Up The Pace On Sustainability And Assess AI Potential
Three UK medtech companies’ views on how their businesses will be influenced by external factors in the coming year.
Times Of Unprecedented Change: German Medtech Readies For Challenging 2024
German medtech and health care are going through a period of unprecedented change and modernization, with hospital reform on the agenda and integration of digitized functionality happening across the sector. The EU Medical Device Regulation casts a long shadow over the medtech industry and will result in a shake out among companies and products, as In Vivo learnt at Medica 2023.
China Biotech To Get More Chills Despite Dealmaking Cheers
Biotech founders and executives in China are embracing uncertainties as the light at the end of the tunnel is still not visible.
Why Did The European Commission Decide All Antimicrobials Should Be Rx-Only?
The European Commission responds to questions regarding its decision to include OTC antivirals and antifungals, including commonly used products like thrush and cold sore creams, in the expanded prescription-only requirements for antimicrobials, as part of proposed measures to combat antimicrobial resistance.
Japan’s CEA Scheme: How It Works And Impact So Far
Japan has announced the latest evaluation results under its cost effectiveness assessment scheme. But how does it work and how much have prices been revised so far under the four-year-old program following discussions between pharma firms and authorities?
In Austrian Life Sciences Sector, Research Is King
There is an opportunity in Austria: the country is teeming with advanced research and strong talent, but much of it remains commercially untapped.
Israeli Biopharma Leaders Focus On Near-Term Targets
Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.
Europe’s Biotech Sector Still In Reasonable Shape
Money may have become too tight to mention for many biotechs and the IPO window in Europe is not just shut but boarded up. However, big pharma’s need to replenish the pipeline has become urgent and the major players are looking to tap into the continent’s early-stage companies which are driving innovation and provide them with much-needed cash.
Syngene Eyes Sweet Spot As New Modalities Hog Limelight
Syngene’s CEO discusses its work in ADC development and trends in the CRDMO space as US biotechs navigate a funding squeeze and manufacturing opportunities loom in areas like GLP- 1 receptor agonists.
How Korea Can Avoid Pitfalls Of Over-Reliance On Out-Licensing
An over-reliance on out-licensing as a business model may restrict the healthy growth of South Korean biopharma firms over the longer term, a Citeline executive told a recent symposium in Seoul.
How The UK Is Reinvigorating Its Clinical Trials Industry
In the year since the Association of the British Pharmaceutical Industry raised the alarm about drastically dwindling clinical trial recruitment numbers in the UK, the country has taken a number of steps to try to turn things around.
Latin America And Caribbean Move Towards Creating A New Regional Regulator
Industry support for a new regional regulator for Latin America and the Caribbean is cautious and experts warn that it could harm competitiveness of the region.
Splits Over Data Protection Could Hamper EU Pharma Revision
The chances of reaching agreement on proposals to overhaul the EU pharma rules before the European Parliament elections in June 2024 are receding as disagreements emerge over key issues such as regulatory data protection and how to encourage antimicrobial R&D.
A Decade At The Top: Lupin MD On Listing Adjacencies, Creating Health Care Continuum
As family-led firms go through a churn in India, Lupin’s MD Nilesh Gupta speaks about adding value via adjacencies to the legacy business, building digital interfaces and a healthcare continuum for patients. In an interview with Scrip, he also emphasized Lupin promoters are neither interested in selling their own stake nor in acquiring that of Cipla’s promoters.
The Growing Pains Of Chinese Biotech
The emergence of China from API manufacturer to an innovation leader, fuelled by domestic investments and home-grown talent, has been one of the most remarkable trends of the last decade.
Innovation Adoption: ‘Medtech’s Ongoing Challenge Of The Day’
UK ministers are increasingly focusing on the need to improve uptake of new technologies in the National Health Service. Ambitious programs have been launched but implementing them effectively for lasting change in a delivery system under acute stress is a challenge of a different order.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.